1. Racial composition in trials supporting the U.S. approval of anti-cancer new molecular entities (NMEs): 2011-2016.;Fashoyin-Aje;J Clin Oncol,2017
2. Under-representation of racial minorities in prostate cancer studies submitted to the US Food and Drug Administration to support potential marketing approval, 1993-2013.;Wissing;Cancer,2014
3. The challenge of targeting EGFR: experience with gefitinib in nonsmall cell lung cancer.;Armour;Eur Respir Rev,2010
4. US Food and Drug Administration Office of Minority Health. Collection of race and ethnicity data in clinical trials: guidance for industry and Food and Drug Administration staff. October 26, 2016. Accessed January 20, 2021. https://www.fda.gov/media/75453/download.
5. US Food and Drug Administration. Enhancing the diversity of clinical trial populations—eligibility criteria, enrollment practices, and trial designs: guidance for industry. November 2020. Accessed February 1, 2021. https://www.fda.gov/media/127712/download